1. Define the role and impact of novel post-allogeneic transplant mechanisms to prevent graft versus host disease
2. Define the impact of blinatumomab consolidation on outcomes in Philadelphia chromosome negative ALL that is without Measurable Residual Disease after induction
3. Interpret the novel contributions but also limitations of the ASAP transplant trial with regards to US-based transplant practice.

Zoom info

Join from a PC, Mac, iPad, iPhone or Android device:

    Please click this URL to join. https://uwmadison.zoom.us/s/94610661159?pwd=bVdSOXYrUW1md2IrRzA5aUJkSnJJdz09

    Passcode: Grand

Or One tap mobile:

    +13092053325,,94610661159# US

    +13126266799,,94610661159# US (Chicago)

Or join by phone:

    Dial(for higher quality, dial a number based on your current location):

        US: +1 309 205 3325  or +1 312 626 6799  or +1 646 931 3860  or +1 929 205 6099  or +1 301 715 8592  or +1 253 215 8782  or +1 346 248 7799  or +1 386 347 5053  or +1 564 217 2000  or +1 669 444 9171  or +1 669 900 6833  or +1 719 359 4580

    Webinar ID: 946 1066 1159

    International numbers available: https://uwmadison.zoom.us/u/ab0ZnlVK3I

Or an H.323/SIP room system:

    H.323: 162.255.37.11 (US West) or 162.255.36.11 (US East)

    Webinar ID: 946 1066 1159

    Passcode: 176874

    SIP: [email protected]

    Passcode: 176874